In the present study we investigated the usefulness of VEGF-A, VEGF-C, VEGF-D and VEGFR-2 separately and in combination with CA 15–3 (commonly used tumor marker) in breast cancer patients not only in the total group of patients but also in particular cancer stage groups (stages I, II, III and IV). This evidence concerns the gene KDR and breast carcinoma.